Trial Profile
A Randomized, Double Blind Study to Compare the Safety and Tolerability of Aleglitazar and Actos [pioglitazone] in Patients With Type 2 Diabetes and NYHA [New York Heart Association] Class II Heart Failure.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Aleglitazar (Primary) ; Pioglitazone
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Roche
- 16 Apr 2008 Status changed from in progress to completed, according to Roche site
- 23 Jan 2008 Updated from Roche site (DMS 23-01-08).
- 23 Jan 2008 Status changed from recruiting to in progress.